Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines dismisses EY, engages KPMG as independent auditor

Neutral Impact 2 of 5 other Written later

Praxis Precision Medicines approved the dismissal of Ernst & Young LLP as its independent registered public accounting firm and engaged KPMG LLP as its new auditor, both effective June 29, 2026. The filing states that EY's reports for fiscal 2025 and 2024 contained no adverse opinion, disclaimer, or qualification, and that no disagreements or reportable events occurred with EY.

Key points

  • Audit Committee approved the dismissal of EY and the engagement of KPMG on June 29, 2026.
  • EY's audit reports for fiscal years 2025 and 2024 had no adverse opinion, disclaimer, or qualification.
  • The company reports no disagreements or reportable events with EY through June 29, 2026.
  • EY's letter to the SEC, dated July 2, 2026, is filed as Exhibit 16.1.

The filing

CompanyPraxis Precision Medicines, Inc. (PRAX)
Form8-K, current report
Filed with the SECJul 2, 2026, 4:30 PM ET
Accession number0001104659-26-080356

Items reported: 4.01 Auditor Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.